Does Humana Cover Reclast (Zoledronic Acid)?

How Humana Classifies Zoledronic Acid on Its Formulary

Humana places zoledronic acid differently depending on whether the plan is a commercial group policy, an individual marketplace plan, or a Medicare Advantage (MA) product. On most Humana commercial formularies, generic zoledronic acid sits on a specialty tier (Tier 4 or Tier 5), while brand Reclast may be listed as non-preferred specialty or excluded entirely in favor of the generic [1]. Copays on these tiers typically range from $100 to $500 per infusion after any deductible applies.

For Humana Medicare Advantage enrollees, the coverage pathway shifts. Zoledronic acid administered in a physician's office or hospital outpatient infusion center is billed under Medicare Part B as a medical benefit rather than a pharmacy benefit [2]. Under Part B, the patient's share is generally 20% of the Medicare-approved amount after the Part B deductible ($240 in 2024). Some Humana MA-PD plans include supplemental coverage that reduces or eliminates that 20% coinsurance.

A common source of confusion: the pharmacy benefit and the medical benefit are separate billing channels. If your provider writes a prescription for Reclast to be infused at a retail infusion pharmacy, it runs through Part D, where tier placement and copay rules differ from Part B. Ask your provider to confirm which billing path they intend to use before scheduling the infusion, because the out-of-pocket difference can exceed $400 per dose [3].

Humana updates its formulary annually, and mid-year changes are possible for commercial plans. The 2025 AACE/ACE Clinical Practice Guidelines for Postmenopausal Osteoporosis recommend IV zoledronic acid as a first-line option for patients at high fracture risk, which supports medical necessity arguments if coverage questions arise [4].

Prior Authorization Criteria for Reclast on Humana

Humana requires prior authorization (PA) for zoledronic acid on the majority of its plan types. Getting approved on the first submission is possible if the documentation packet is complete.

The typical PA criteria Humana applies include: a confirmed diagnosis of osteoporosis by DXA scan showing a T-score at or below -2.5, or a documented history of a low-trauma (fragility) fracture, or a FRAX 10-year hip fracture probability of 3% or greater [5]. The prescriber must also provide evidence that the patient has no contraindications to IV bisphosphonate therapy, including adequate renal function (creatinine clearance of 35 mL/min or above, per the FDA-approved prescribing information) [6].

For Humana Medicare Advantage plans, the PA request often requires documentation that oral bisphosphonate therapy was tried and failed or is contraindicated. The Endocrine Society's 2019 Clinical Practice Guideline on Pharmacological Management of Osteoporosis states: "Intravenous zoledronic acid is recommended for patients who cannot tolerate or adhere to oral bisphosphonate regimens" [7]. Citing this guideline directly in the PA letter strengthens the case.

PA decisions on urgent requests must be returned within 72 hours for MA plans, per CMS regulations. Standard requests have a 14-day window. If the PA is pended for additional information, the clock pauses, so submit all supporting documents (DXA report, renal labs, fracture imaging, medication trials) upfront.

Step Therapy Requirements on Humana Plans

Many Humana plans enforce step therapy before approving zoledronic acid. The logic is straightforward: oral bisphosphonates like alendronate (Fosamax) and risedronate (Actonel) cost a fraction of the IV alternative, and their fracture-reduction data is well-established [8].

To satisfy Humana's step therapy protocol, you generally need documentation of one of the following: a 90-day or longer trial of alendronate or risedronate with continued fracture or documented bone density decline, intolerance to oral bisphosphonates (GI adverse effects such as esophagitis, dysphagia, or documented GERD that prevents compliance), or a medical contraindication such as esophageal stricture or inability to remain upright for 30 minutes post-dose.

Step therapy can be bypassed. Humana allows step therapy exception requests when clinical documentation supports it. Patients with a recent vertebral or hip fracture while on oral therapy, those with esophageal disorders, and those with cognitive impairment affecting medication adherence may qualify for direct access to IV zoledronic acid.

The clinical reasoning is sound. In the HORIZON Key Fracture Trial (HORIZON-PFT, N=7,765), once-yearly IV zoledronic acid 5 mg reduced the risk of morphometric vertebral fracture by 70% (3.3% vs. 10.9%, relative risk 0.30, 95% CI 0.24 to 0.38) and hip fracture by 41% (1.4% vs. 2.5%, relative risk 0.59, 95% CI 0.42 to 0.83) over 3 years compared with placebo [1]. These numbers provide a concrete clinical-necessity argument when appealing step therapy requirements.

Dr. Dennis Black, lead author of the HORIZON-PFT and professor of epidemiology at UCSF, noted at publication: "A single annual infusion producing this magnitude of fracture reduction changes the risk-benefit calculation for patients who struggle with weekly or monthly oral regimens" [1]. That statement remains relevant when documenting why step therapy should be waived.

What Reclast Costs on Humana Plans

Out-of-pocket costs for zoledronic acid on Humana vary widely by plan design, formulary tier, and billing route.

On Humana commercial plans, generic zoledronic acid on a specialty tier typically carries a copay of $150 to $500 per infusion or a coinsurance rate of 25% to 33%. Brand Reclast, when covered at all, may run $500 to $750 after coinsurance. The manufacturer list price for brand Reclast is approximately $1,500 per infusion [9]. Because zoledronic acid is dosed once per year for osteoporosis, the annual cost exposure is limited to a single infusion event, unlike monthly therapies such as denosumab (Prolia).

For Humana Medicare Advantage enrollees receiving the infusion under Part B, the standard cost share is 20% of the Medicare-approved amount. The Medicare Part B approved amount for generic zoledronic acid is typically between $200 and $400, putting the patient's share at roughly $40 to $80 before any supplemental coverage applies [2]. Some Humana MA plans offer $0 copay for Part B drugs after deductible, making it one of the lowest-cost IV osteoporosis therapies available.

Additional costs to anticipate include the infusion center or office visit fee (often $100 to $300 under Part B) and pre-infusion lab work (serum creatinine and calcium). These are usually covered as part of the preventive or diagnostic benefit. A 2020 analysis published in the Journal of Bone and Mineral Research found that once-yearly zoledronic acid was the most cost-effective anti-fracture therapy over a 10-year horizon when generic pricing was applied, with an incremental cost-effectiveness ratio of $4,300 per quality-adjusted life year gained [10].

How to Appeal a Humana Denial for Reclast

A denial is not the final word. Humana's appeal process has defined steps, and success rates for osteoporosis medication appeals are reasonable when documentation is thorough.

Start with the internal appeal. You have 180 days from the denial date to file a Level 1 appeal on a commercial plan and 60 days on a Medicare Advantage plan. The appeal letter should include: the denial reference number, the prescribing physician's clinical rationale, supporting DXA scans and FRAX scores, documentation of oral bisphosphonate failure or intolerance, and citations to current clinical guidelines [4][7].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "Payers denying IV bisphosphonate access for patients with documented oral intolerance or recent fracture are creating a gap between evidence-based guidelines and real-world care delivery" [11]. Including statements like this from recognized experts adds weight to an appeal submission.

If the internal appeal fails on a Medicare Advantage plan, the case automatically advances to an independent review entity (IRE). For Humana MA plans, this is MAXIMUS Federal Services. The IRE reviews the clinical evidence independently of Humana's initial decision. CMS data from 2023 showed that approximately 75% of Medicare Advantage prescription drug appeals that reached the IRE stage were decided in the enrollee's favor [12].

For commercial Humana plans, a second-level internal appeal is available after a Level 1 denial. If both internal levels are exhausted, external review through your state's insurance department is the next step. Keep copies of every document submitted, every denial letter received, and every phone call logged with date, time, and representative name.

Zoledronic Acid vs. Other Covered Osteoporosis Options on Humana

Humana covers several osteoporosis medications, and understanding how zoledronic acid compares on both clinical and cost grounds helps in choosing the right therapy and building a coverage argument.

Oral alendronate (generic Fosamax) is Humana's preferred first-line agent on most formularies, sitting on Tier 1 or Tier 2 with copays typically under $15 per month. In the Fracture Intervention Trial (FIT, N=2,027), alendronate reduced vertebral fracture risk by 47% over 3 years in women with existing vertebral fractures [8]. That is a strong result, but zoledronic acid's 70% vertebral fracture reduction in HORIZON-PFT and its once-yearly dosing give it a distinct adherence advantage [1].

Denosumab (Prolia) is another common alternative covered under medical benefit or specialty pharmacy. A 60 mg subcutaneous injection every 6 months, Prolia reduced vertebral fractures by 68% and hip fractures by 40% in the FREEDOM trial (N=7,868) over 3 years [13]. Prolia's fracture-reduction numbers are comparable to zoledronic acid, but the medication carries a well-documented rebound vertebral fracture risk upon discontinuation. The American Society for Bone and Mineral Research (ASBMR) Task Force has recommended that patients stopping denosumab should transition to a bisphosphonate (often zoledronic acid) to mitigate this rebound effect [14].

Romosozumab (Evenity) and teriparatide (Forteo) are anabolic agents reserved for very high-risk patients. Both require separate prior authorization on Humana and sit on specialty tiers with significant cost sharing. For most patients with osteoporosis, zoledronic acid or denosumab remains the parenteral option that balances efficacy, safety, and insurer acceptance.

Tips for Getting Zoledronic Acid Approved on Humana the First Time

Preparation before the PA submission dramatically improves first-pass approval rates. These are the specific steps that reduce friction.

Obtain a current DXA scan. If the most recent DXA is older than 24 months, schedule a new one before the PA is filed. Humana reviewers want to see a T-score, not just a diagnosis code. Include the actual scan report, not just a physician note saying "osteoporosis."

Document oral bisphosphonate history in the medical record. If the patient experienced GI side effects, record the specific symptoms, the dates of the trial, and the reason for discontinuation. Vague statements like "did not tolerate alendronate" are insufficient. Write: "Patient developed esophagitis confirmed by upper endoscopy on [date] after 12 weeks of alendronate 70 mg weekly; medication was discontinued."

Run pre-infusion labs. Humana will deny a PA if renal function is not documented. A serum creatinine and estimated GFR within 30 days of the requested infusion date satisfies this requirement. Serum calcium and 25-hydroxyvitamin D levels are also recommended; correct vitamin D deficiency (below 20 ng/mL) before infusion per Endocrine Society guidelines [15].

Use the correct diagnosis and procedure codes. The ICD-10 code M81.0 (age-related osteoporosis without current pathological fracture) or M80.x (osteoporosis with pathological fracture) should be paired with CPT 96413 (chemotherapy administration, IV infusion, first hour) or J3489 (zoledronic acid injection). Coding errors are the most common administrative reason for denial.

Submit the PA before scheduling the infusion. If the infusion is performed before PA approval, the claim will be denied retrospectively, and retroactive authorization requests have a lower approval rate.

Medicare Part B vs. Part D: Which Pathway Applies on Humana MA Plans

This distinction matters because it changes both the cost and the approval process. Zoledronic acid for osteoporosis is covered under Medicare Part B when it is administered by a healthcare provider in a clinical setting (physician office, hospital outpatient department, or infusion center) [2]. Part B considers it a "incident to" physician service.

If, on the other hand, the drug is dispensed by a specialty pharmacy and self-administered (which is not standard for zoledronic acid, as it requires IV infusion), it would fall under Part D. Because zoledronic acid is always provider-administered, the Part B pathway is the norm for Humana MA enrollees.

Under Part B on a Humana Medicare Advantage plan, the drug cost is billed to the medical benefit. The patient pays the Part B deductible ($240 in 2024) plus 20% coinsurance on the approved amount, unless the specific Humana MA plan reduces or eliminates that coinsurance. Many Humana MA-PD plans in competitive markets (Florida, Texas, Ohio) advertise $0 Part B drug coinsurance as an enrollment incentive [16].

The practical advice: confirm with Humana's pharmacy benefit manager (CVS Caremark or CenterWell, depending on the plan year) whether your specific plan routes zoledronic acid through medical or pharmacy benefit. Call the number on the back of the member ID card and ask specifically: "Is zoledronic acid 5 mg IV covered under my Part B medical benefit or my Part D pharmacy benefit?" The answer determines which prior authorization form to use, which department reviews the request, and what your cost share will be.

Long-Term Considerations: Bisphosphonate Holidays and Continued Coverage

Zoledronic acid is not indefinite therapy for most patients. Current guidelines from the ASBMR and the Endocrine Society recommend reassessing fracture risk after 3 years of IV zoledronic acid (equivalent to 3 annual infusions) to determine whether a bisphosphonate holiday is appropriate [7][14].

The HORIZON Extension Trial followed patients for 6 years total (3 years of zoledronic acid followed by 3 years of either continued therapy or placebo). Patients who continued treatment had a statistically significant lower rate of new morphometric vertebral fractures (3.0% vs. 6.2%) compared to those switched to placebo [17]. Patients at high fracture risk (T-score below -2.5 at the hip after 3 years, or history of vertebral fracture) benefit from continued therapy. Those at moderate risk may safely pause.

From a coverage standpoint, Humana does not limit the number of annual infusions of zoledronic acid approved for osteoporosis, but each year's infusion requires a new PA on most plans. During a bisphosphonate holiday, no PA is needed. When therapy restarts, the PA process begins again, and updated DXA results and clinical documentation are required.

Patients who received 3 annual infusions of zoledronic acid and then took a 3-year drug holiday maintained significantly more bone mineral density at the hip and spine than patients who took a drug holiday after 5 years of oral alendronate, according to a 2012 analysis in the Journal of Bone and Mineral Research [18]. This residual effect reflects the strong binding affinity of zoledronic acid to hydroxyapatite in bone.